The BENEFIT Trial: Where do we go from here?
Benznidazole Evaluation for Interrupting Trypanosomiasis evaluates the safety of benznidazole in patients with Chagasic cardiomyopathy
Abstract
The commentary in this article discusses the results and implications of the recently published BENEFIT trial.The Benznidazole Evaluation for Interrupting Trypanosomiasis (BENEFIT) trial was designed to evaluate the safety and efficacy of benznidazole in patients with Chagasic cardiomyopathy.
In the next 5 years, we can now project that 200,000 people living with Chagas disease will die from heart disease and related complications. We urgently need to redouble our efforts to identify and treat young people who are still in the early stages of their illness, but ultimately we need to find better treatments and new cures.
This is an output from the Drugs for Neglected Diseases initiative (DNDi) programme
Citation
Pecoul B, Batista C, Stobbaerts E, Ribeiro I, Vilasanjuan R, Gascon J, et al. (2016) The BENEFIT Trial: Where Do We Go from Here? PLoS Neglected Tropical Diseases 10(2) https://doi.org/10.1371/journal.pntd.0004343